Abstract
Background Diagnoses of HIV in the US decreased by 17% in 2020 due to COVID-related disruptions. The extent to which this decrease is attributable to changes in HIV testing versus HIV transmission is unclear. We seek to better understand this issue by analyzing the discrepancy in expected versus observed HIV diagnoses in 2020 among persons who acquired HIV between 2010-2019, as changes in diagnosis patterns in this cohort cannot be attributed to changes in transmission.
Methods We developed three methods based on the CD4-depletion model to estimate excess missed diagnoses in 2020 among persons with HIV (PWH) infected from 2010-2019. We stratified the results by transmission group, sex assigned at birth, race/ethnicity, and region to examine differences by group and confirm the reliability of our estimates. We performed similar analyses projecting diagnoses in 2019 among PWH infected from 2010-2018 to evaluate the accuracy of our methods against surveillance data.
Results There were approximately 3100-3300 (approximately 18%) fewer diagnoses than expected in 2020 among PWH infected from 2010-2019. Females (at birth), heterosexuals, persons who inject drugs, and Hispanic/Latino PWH missed diagnoses at higher levels than the overall population. Validation and stratification analyses confirmed the accuracy and reliability of our estimates.
Conclusions The substantial drop in number of previously infected PWH diagnosed in 2020, suggests that changes in testing played a substantial role in the observed decrease. Levels of missed diagnoses differed substantially across population subgroups. Increasing testing efforts and innovative strategies to reach undiagnosed PWH are needed to offset this diagnosis gap. These analyses may be used to inform future estimates of HIV transmission during the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used for this analysis was collected as part of the public health program activity called PS18-1802 Integrated HIV Surveillance and Prevention Programs for Health Departments (Component A), which is a routine disease surveillance activity across 60 jurisdictions throughout the U.S. A project determination made by the National Center for HIV, Hepatitis, STD, and TB Prevention (NCHHSTP) on behalf of The Centers for Disease Control and Prevention (CDC) on January 22, 2018 determined this project to be exempt from needing IRB review as it is not human subjects research. The National Center for HIV, Hepatitis, STD, and TB Prevention (NCHHSTP) on behalf of The Centers for Disease Control and Prevention (CDC) approved the use of this data in the current document on August 25, 2022.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclaimer: The data used for this analysis was collected as part of the public health program activity called PS18-1802 Integrated HIV Surveillance and Prevention Programs for Health Departments (Component A), which is a routine disease surveillance activity across 60 jurisdictions throughout the U.S. A project determination made by the National Center for HIV, Hepatitis, STD, and TB Prevention (NCHHSTP) on behalf of The Centers for Disease Control and Prevention (CDC) on January 22, 2018 determined this project to be exempt from needing IRB review as it is not human subjects research. The National Center for HIV, Hepatitis, STD, and TB Prevention (NCHHSTP) on behalf of The Centers for Disease Control and Prevention (CDC) approved the use of this data in the current document on August 25, 2022.
3 Note that this sum includes smaller racial/ethnic groups, not listed due to small population sizes.
4 Note that this sum includes smaller racial/ethnic groups, not listed due to small population sizes.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
